A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations.

A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations.

The SARS-CoV-2 main protease (Mpro) is a major therapeutic target. The Mpro inhibitor, nirmatrelvir, is the antiviral component of Paxlovid, an orally available treatment for COVID-19. As Mpro inhibitor use increases, drug resistant mutations will likely emerge. We have established a non-pathogenic...

Full description

Bibliographic Details
Main Authors: Jin Ou, Eric M Lewandowski, Yanmei Hu, Austin A Lipinski, Ali Aljasser, Mariliz Colon-Ascanio, Ryan T Morgan, Lian M C Jacobs, Xiujun Zhang, Melissa J Bikowitz, Paul R Langlais, Haozhou Tan, Jun Wang, Yu Chen, John S Choy
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-08-01
Series:PLoS Pathogens
Online Access:https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1011592&type=printable

Internet

https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1011592&type=printable

Similar Items